White House Deficit Reduction Plan Targets Biologic Exclusivity Period - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

White House Deficit Reduction Plan Targets Biologic Exclusivity Period


ePT--the Electronic Newsletter of Pharmaceutical Technology

President Obama released his plan for deficit reduction on Sept. 19, 2011, and included in the 80-page report are several provisions that would affect US drug makers if enacted. The first is a proposal to reduce the period of exclusivity for biologics from the current 12 years to seven years. In addition, the practice of evergreening—extending the exclusivity period by making minor changes in product formulation—would be prohibited. According to the report, “The Administration’s proposal strikes a balance between promoting affordable access to medications and encouraging innovation to develop needed therapies. The proposal will result in $3.5 billion in savings over 10 years to federal health programs including Medicare and Medicaid.”

Another provision would give the Federal Trade Commission the authority to prohibit pay-for-delay agreements, in which a manufacturer of an innovator product pays to delay the entry of a generic drug onto the market. The proposal is intended to increase patient access to generic drugs and biologics, and the administration projects that the policy would save federal health programs $2.7 billion over 10 years.

Also included in the plan is a proposal to align Medicare drug-payment policies with Medicaid policies for low-income beneficiaries. The plan would require the same drug rebates that are offered to Medicaid recipients to be offered under Medicare Part D. It is estimated that the policy change would result in $135 billion in savings over 10 years.


See related Pharm Tech articles:

FTC Finds 60% Increase in Pay-to-Delay Deals (ePT)

Health-Reform Controversies (Pharmaceutical Technology)

PhRMA Opposes Changes to Medicare Part D (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here